Brokerages Expect United Therapeutics Co. (UTHR) Will Post Earnings of $3.64 Per Share

Analysts forecast that United Therapeutics Co. (NASDAQ:UTHR) will announce earnings per share (EPS) of $3.64 for the current quarter, according to Zacks Investment Research. Five analysts have made estimates for United Therapeutics’ earnings, with the highest EPS estimate coming in at $4.46 and the lowest estimate coming in at $2.65. United Therapeutics posted earnings of $3.89 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 6.4%. The business is expected to report its next quarterly earnings results on Wednesday, April 25th.

On average, analysts expect that United Therapeutics will report full-year earnings of $12.46 per share for the current year, with EPS estimates ranging from $10.66 to $14.68. For the next financial year, analysts expect that the business will report earnings of $10.83 per share, with EPS estimates ranging from $8.31 to $12.39. Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for United Therapeutics.

How to Become a New Pot Stock Millionaire

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings results on Wednesday, February 21st. The biotechnology company reported $3.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.59 by $0.30. United Therapeutics had a return on equity of 24.41% and a net margin of 24.22%. The business had revenue of $464.70 million for the quarter, compared to analyst estimates of $420.55 million. During the same period last year, the company earned $4.12 EPS. United Therapeutics’s revenue for the quarter was up 13.6% compared to the same quarter last year.

Several equities analysts recently issued reports on the company. BidaskClub upgraded United Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday. ValuEngine lowered United Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, February 27th. Credit Suisse Group restated an “underperform” rating and set a $115.00 price target (down from $120.00) on shares of United Therapeutics in a research report on Thursday, February 22nd. TheStreet upgraded United Therapeutics from a “c+” rating to a “b” rating in a research report on Friday, December 15th. Finally, Oppenheimer raised their price target on United Therapeutics to $180.00 and gave the stock an “outperform” rating in a research report on Friday, January 5th. Five investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $135.20.

United Therapeutics stock opened at $107.39 on Thursday. The company has a current ratio of 3.26, a quick ratio of 3.01 and a debt-to-equity ratio of 0.12. United Therapeutics has a 1 year low of $106.30 and a 1 year high of $152.55. The stock has a market capitalization of $4,643.54, a P/E ratio of 9.79 and a beta of 1.32.

In other news, CEO Martine A. Rothblatt sold 301 shares of United Therapeutics stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $110.48, for a total value of $33,254.48. Following the sale, the chief executive officer now directly owns 21,652 shares in the company, valued at approximately $2,392,112.96. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Martine A. Rothblatt sold 43,025 shares of United Therapeutics stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $111.11, for a total value of $4,780,507.75. Following the completion of the sale, the chief executive officer now owns 21,652 shares in the company, valued at $2,405,753.72. The disclosure for this sale can be found here. Over the last quarter, insiders sold 65,938 shares of company stock worth $7,355,949. Corporate insiders own 7.80% of the company’s stock.

Several hedge funds have recently modified their holdings of the company. Xact Kapitalforvaltning AB grew its position in shares of United Therapeutics by 3.8% in the 4th quarter. Xact Kapitalforvaltning AB now owns 11,474 shares of the biotechnology company’s stock worth $1,698,000 after buying an additional 424 shares during the last quarter. SG Americas Securities LLC grew its position in shares of United Therapeutics by 4.2% in the 3rd quarter. SG Americas Securities LLC now owns 10,799 shares of the biotechnology company’s stock worth $1,266,000 after buying an additional 436 shares during the last quarter. Pacer Advisors Inc. grew its position in shares of United Therapeutics by 6.9% in the 3rd quarter. Pacer Advisors Inc. now owns 7,188 shares of the biotechnology company’s stock worth $842,000 after buying an additional 461 shares during the last quarter. ETRADE Capital Management LLC lifted its stake in shares of United Therapeutics by 18.8% in the 4th quarter. ETRADE Capital Management LLC now owns 2,937 shares of the biotechnology company’s stock valued at $435,000 after purchasing an additional 465 shares during the period. Finally, Amalgamated Bank lifted its stake in shares of United Therapeutics by 6.0% in the 4th quarter. Amalgamated Bank now owns 8,685 shares of the biotechnology company’s stock valued at $1,285,000 after purchasing an additional 489 shares during the period.

TRADEMARK VIOLATION NOTICE: This piece of content was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark laws. The correct version of this piece of content can be accessed at https://www.tickerreport.com/banking-finance/3299618/brokerages-expect-united-therapeutics-co-uthr-will-post-earnings-of-3-64-per-share.html.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Get a free copy of the Zacks research report on United Therapeutics (UTHR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Astro 24-Hour Volume Reaches $3,638.00
Astro 24-Hour Volume Reaches $3,638.00
SyncFab Hits One Day Trading Volume of $45,979.00
SyncFab Hits One Day Trading Volume of $45,979.00
Microsoft Co.  Expected to Post Quarterly Sales of $25.71 Billion
Microsoft Co. Expected to Post Quarterly Sales of $25.71 Billion
Zacks: Analysts Anticipate Shutterstock  Will Announce Quarterly Sales of $150.17 Million
Zacks: Analysts Anticipate Shutterstock Will Announce Quarterly Sales of $150.17 Million
$8.32 Billion in Sales Expected for Enterprise Products  This Quarter
$8.32 Billion in Sales Expected for Enterprise Products This Quarter
Akamai Technologies  Expected to Post Quarterly Sales of $654.02 Million
Akamai Technologies Expected to Post Quarterly Sales of $654.02 Million


© 2006-2018 Ticker Report. Google+.